



Prostate cancer is the second most common cause of cancer 
death after lung cancer.[1] The incidence is higher among 
the black race.[2] A hospital prevalence of 127–182.5 per 
100,000 has been reported by many urologists in sub-Saharan 
Africa.[3,4] Transrectal needle biopsy of the prostate (TNBP) 
is the established mode of obtaining tissue for histological 
diagnosis in men who are suspected to harbor the disease.[5,6]
Although infective complications after TNBP are infrequent, most 
investigators suggest the use of prophylactic antibiotics.[7,8] While 
some prospective studies recommend short-term (one–three 
days) antibiotic prophylaxis,[9,10] others favor long-term (four–
seven days) antibiotic prophylaxis.[11,12] Recent reviews have 
shown that fluoroquinolones are a good choice for prophylaxis 
as most of the frequently found organisms following TNBP are 
susceptible to these groups of antibiotics.[9,13] Metronidazole is 
often added to the fluoroquinolones to cover for both coliforms 
and anaerobes which are likely to cause infections after 
TNBP.[14,15] McArdle et al.[16] noted that the use of ciprofloxacin 
and metronidazole during colorectal surgery significantly 
decreased surgical site infections.
Several works on antibiotics prophylaxis in TNBP have 
demonstrated that the time of initiation of prophylactic antibiotics 
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plays an important role in infective complications associated with 
prostate biopsy.[17-20] In this era of antibiotic resistance and the 
high cost of antibiotic agents, an effective short‑course regimen 
for prophylaxis in TNBP would be of benefit to both patients and 
surgeons. This study aims to compare the outcome of a three-day 
and seven-day antibiotic prophylaxis in TNBP.
MaterIals and Methods
This is a prospective hospital-based comparative study. Patients 
with prostate‑specific antigen (PSA) of above 4 ng/ml, who 
had suspicious digital rectal examination (DRE) findings, or 
prostate ultrasound findings suggestive of prostate cancer were 
enrolled in the study. All participants had pre-biopsy urine 
culture done. Men with positive pre-biopsy urine culture were 
excluded from the study. They were, however, treated with 
antibiotics in accordance with the sensitivity pattern.
The recruited patients were randomly allocated to two groups 
using a computer-generated table of random numbers.[21] Patients 
in Group I received oral ciprofloxacin (500 mg) 12 hourly and 
oral metronidazole (400 mg) 8 hourly for three days, starting 
two hour before the biopsy. Patients in Group II received the 
same antibiotics for seven days, also starting two hours before 
the biopsy.
All the patients underwent TNBP. An 18G Tru-Cut biopsy 
needle was used and 12 cores of tissue were taken according 
to the unit protocol. No form of bowel preparation was done. 
The patients were allowed home after an hour of observation. 
Patients in Group I were requested to attend for follow-up on 
the fifth and 10th days after the biopsy and those in Group II on 
the 10th and 14th day after the biopsy. All patients were told to 
return to the hospital in case of any complication(s). They were 
provided with telephone numbers to call in case of an emergency 
and an easy-to-use digital clinical thermometer for a twice-daily 
recording of their body temperature for the first 14 days after the 
procedure. All patients were questioned concerning symptoms 
of infective complications. Mid-stream urine samples were 
obtained for microscopy, culture, and sensitivity (m/c/s) during 
follow‑up visits on days five and 10 for Group I and at days 10 
and 14 for Group II. A structured pro forma was used to record 
relevant information for all patients.
Positive culture (≥105 colony forming units per ml) indicated 
urinary tract infection, irrespective of symptoms.[13] Fever 
was defined as any temperature >38°C recorded in the first 
14 days after the biopsy.[22] Blood culture was obtained only 
in patients who reported back to the hospital on account 
of post-biopsy fever. This was after a history and physical 
examination had been carried out to rule out other causes 
of fever. Post-biopsy fever and positive urine cultures were 
regarded as indicators of infection after the biopsy.
All patients signed informed consent before taking part 
in this study. The Ethics Committee of Irrua Specialist 
Teaching Hospi ta l  gave approval  for  the  s tudy 
(Approval No: ISTH/HREC/2016/MARCH/27).
results
One hundred and twenty patients took part in this study. They 
were randomized into two groups of 60 patients each. The 
majority of the patients (n = 92 [76.7%]) were in their seventh 
and eighth decades of life [Figure 1]. The mean age of the 
participants was 69.8 ± 9.1 years. There was no statistically 
significant difference between the ages of patients in both 
groups (P = 0.381).
The mean PSA level was 36.6 ± 45.2 ng/ml (range: 5.7–310.2). 
The mean prostate size was 101.4 ± 91.4 g. There was no 
statistically significant difference between patients in Groups I 
and II in terms of means of PSA level (P = 0.218) and prostate 
size (P = 0.233). The risk factors for infective complications 
were similar in both groups [Table 1].
Indications for prostate biopsy in this study were elevated PSA 
and abnormal DRE findings in 67 (55.8%), elevated PSA only 
in 47 (39.2%), and abnormal DRE findings only in six (5.0%).
All non-infective complications were self-limiting. There 
was, however, no statistically significant difference 
between Group I and Group II in terms of haematuria 
(P = 0.512), perineal pain (P = 0.306), rectal bleeding 
(P = 0.125), acute urinary retention (P = 0.679), and 
haemospermia (P = 0.619) [Figure 2].
A total of 19 (15.8%) patients had a positive urine culture. Of 
these, 13 were in Group I, while six were in Group II. The 
organisms cultured are shown in Figure 3.
Twelve (10%) patients out of the 120 had a post-biopsy fever. 
Of these, nine (75%) were in Group I, while three (25%) were 
in Group II. There was no statistically significant difference 
between the two groups in terms of fever (P = 0.165). 
Five (41.7%) patients reported back to the hospital and had 
a blood culture done in addition to the urine culture. Of these 
five who had blood culture done, 4 had no growth, while one 
grew Escherichia coli. Four patients (all in Group II) required 
treatment with oral antibiotics. The patient (in Group I), 
whose blood culture grew Escherichia coli, was admitted and 
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Figure 1: Age distribution of patients in decades
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treated for septicemia with parenteral antibiotics. There was 
no statistically significant difference between the sensitivity 
pattern of Group I and Group II (P = 0.192) [Table 2].
A significantly higher proportion of diabetic patients had 
infective complications in Group I (X2 = 18.330, df = 1, P < 0.001). 
Similarly, a greater percentage of patients who were hospitalized 
within 14 days before biopsy had infective complications in 
Group I and this was significant (X2 = 4.404, df = 1, P = 0.035) 
[Tables 3 and 4].
Of the 120 men, 78 (65%) had adenocarcinoma of the 
prostate, 35 (29.20%) had benign prostatic hyperplasia, 
four (3.3%) had prostatic intraepithelial neoplasia, and in 
three (2.50%), the prostate tissues were not enough for 
histological examination. The mean Gleason’s score of the 
patients with prostatic adenocarcinoma was 7.0 (±1.5). The 
majority of these patients (64 out of the 78) had Gleason’s 
score >6.
dIscussIon
There is no general agreement among urological surgeons on 
antimicrobial prophylaxis for prostate biopsy. The type and 
duration of the antibiotics used are still a subject of debate.[11-13] 
There is also a controversy about which organisms play a major 
role in post-biopsy infections. Even the timing of antibiotics 
administration differs in various works. All these factors make 
direct comparisons among different studies difficult.[6-9]
Age remains the strongest risk factor for carcinoma of the 
prostate.[2] The peak age range in this study was 70–79 years. 
This was similar to what was reported by Badmus et al.[4] and 
Eke[23] among African patients. However, workers in Europe 
and the United States have reported a peak age range of 
60–69 years.[5,8,10] This difference may be because patients 
usually present late in our environment.[4]
Indications for TNBP include elevated PSA, abnormal DRE, 
and transrectal ultrasound scan findings. In consonance with 
reports by Sieber et al.[7] and Bootsma et al.,[8] the most common 
indication for prostate biopsy in this study was elevated PSA 
(92.5%). The mean PSA level of 36.6 (±45.2) ng/ml is high 
when compared to similar works that showed PSA ranges 
from 11.23 ± 6.8 ng/ml to 18.6 ± 22.4 ng/ml.[19,24] This high 
PSA level may mean that our patients present at the advanced 
stage of the disease like has been variously reported in previous 
studies in our environment where there are no screening 
protocols.[4,19,24] This finding buttresses the need for more 
public enlightenment and health education to ensure the early 
detection and management of this disease.
The reported incidence of complications after TNBP ranges from 
2% to 79%.[5,7,9,25] These complications are grouped into infective 
Table 1: Risk factors for infective complications in Group I and II
Risk factors Prophylaxis group, frequency (%) Statistics (χ2, df, P)
Group I Group II
Diabetes mellitus
Yes 6 (37.5) 10 (62.5) 1.154, 1, 0.283
No 54 (51.9) 50 (48.1)
Antibiotics use within the last 14 days
Yes 17 (60.7) 11 (29.3) 1.677, 1, 0.195
No 43 (46.7) 49 (53.3)
Hospitalization within the last 14 days
Yes 4 (66.7) 2 (33.3) 0.702, 1, 0.679†
No 56 (49.1) 58 (50.9)
Hypertension
Yes 14 (40.0) 21 (60.0) 1.976, 1, 0.160
No 46 (54.1) 39 (45.9)
Prolonged steroid use
Yes 1 (100.0) 0 1.008, 1, 0.000†
No 59 (49.6) 60 (50.4)
Presence of indwelling catheter
Yes 28 (47.5) 31 9 (52.5) 0.300, 1, 0.584
No 32 (52.5) 29 (47.5)
†Fisher’s exact. χ2: Pearson Chi-square
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Table 2: Sensitivity pattern of postbiopsy cultured 
organisms
Drugs* Group, frequency







Multidrug resistance 2 -
*Multiple sensitivities applied. P=0.192
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Table 3: Association between postbiopsy infective complications and risk factors for infective complications in group I
Risk factors Infective complications, frequency (%) Statistics (χ2, df, P)
Yes No
Diabetes mellitus
Yes 6 (100.0) 0 18.330, 1, <0.001
No 10 (18.5) 44 (81.5)
Antibiotics use within the last 14 days
Yes 5 (29.4) 12 (70.6) 0.091, 1, 0.762
No 11 (25.6) 32 (74.4)
Hospitalization within the last 14 days Yes 3 (75.0) 1 (25.0) 5.120, 1, 0.054†
No 13 (23.2) 43 (76.8)
Hypertension
Yes 5 (35.7) 9 (64.3) 0.764, 1, 0.382
No 11 (23.9) 35 (76.1)
Prolonged steroid use
Yes 0 1 (100.0) 0.370, 1, 1.000†
No 16 (27.1) 43 (72.9)
†Fisher’s exact. χ2: Pearson Chi-square
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and non-infective complications. Although prophylactic 
antibiotics minimize the infective complications following 
TNBP, it does not eliminate them. Overall, the complication 
rate in this work was 54.21%. Most of these complications 
were inconsequential and self-limiting. Shittu and Kamara[25] 
in Ibadan documented a lower complication rate (26%) using 
a three-day antibiotics prophylaxis. In his work, 3–6 core 
tissues were taken which may account for the difference in 
the complication rates. The non-infective complication rate 
observed in this study was 43.3%. This was similar to those seen 
in other studies.[7,25] Haemorrhagic complications consisting of 
haematuria, rectal bleeding, and haemospermia predominated 
accounting for 40.8% of the non-infective complications.
The effectiveness of antibiotic prophylaxis in reducing infective 
complications in TNBP was first reported by Crawford et al.[26] 
in 1982. In a work by Aron et al.,[15] ciprofloxacin and tinidazole 
combination was shown to be sufficient in preventing infective 
complications following TNBP in selected persons. In this 
study, post-biopsy fever and positive urine cultures were 
regarded as indicators of infection, as in other studies.[6,8,9,26] 
Post-procedure fever was noted in 10% of patients. Prior 
publications had noted fever ranging from 1.7% to 6.3%.[27-30] 
15.8% positive urine cultures documented in this study were 
higher than the rates documented in some series.[27,28,30]
Quoted figures for hospitalization following TNBP range 
from 0.3% to 0.6%.[27,29] Urosepsis occurred in one (0.8%) 
patient in this study and required admission and treatment 
with parenteral antibiotics. This was the only serious infective 
complication observed in this study. This hospitalization rate of 
0.8% is in keeping with the rates following TNBP seen in other 
Table 4: Association between postbiopsy infective complications and risk factors for infective complications in Group II
Risk factors Infective complications, frequency (%) Statistics (χ2, df, P)
Yes No
Diabetes mellitus
Yes 2 (20.0) 8 (80.0) 0.809, 1, 0.330†
No 5 (10.0) 45 (90.0)
Antibiotics use within the last 14 days
Yes 2 (18.2) 9 (81.8) 0.555, 1, 0.602†
No 5 (10.2) 44 (89.8)
Hospitalization within the last 14 days
Yes 0 2 (100.0) 0.273, 1, 1.000†
No 7 (12.1) 51 (87.9)
Hypertension
Yes 5 (23.8) 16 (76.2) 4.622, 1, 0.045†
No 2 (5.1) 37 (94.9)
Prolonged steroid use
Yes 7 (11.7) 53 (88.3) χ2: uniform cells
No 7 (11.7) 53 (88.3)
†Fisher’s exact. χ2: Pearson Chi-square
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studies.[27-29] This sepsis rate of 0.8% may reflect a relatively 
low rate of fluoroquinolone resistance in our environment. This 
is in contrast to a work done in North America that showed an 
increased rate of post-biopsy sepsis probably due to a rising 
bacterial resistance.[5] Complications such as acute prostatitis, 
epididymo-orchitis, and prostatic and ischiorectal abscesses 
reported in the literature[19,31] were absent in this study. These 
complications may be regarded as rare even in the presence 
of risk factors for infective complications.
There was no statistically significant difference between 
Group I and Group II in terms of post-procedure fever and 
positive urine culture (P = 0.068 for fever and P = 0.166 for 
positive urine culture). A similar study done to determine 
the difference in infective outcome between a single and 
a five‑day course of prulifloxacin showed no significant 
difference between the two groups of patients studied 
(0.95% and 0.90%).[7] This may mean that the availability 
of antibiotics in the bloodstream and the prostate during 
a prostate biopsy is more important than the duration of 
antimicrobial prophylaxis in determining post-biopsy 
infective complications.
Some workers have identified both patient and procedural factors 
that may predispose patients to infective complications.[32-34] 
Patient‑specific risk factors identified include diabetes mellitus,
prolonged steroid use, preexisting urinary tract infections, 
and recent hospitalization.[35,36] Prolong indwelling urethral 
catheter has also been noted as a risk factor for post-
biopsy infective complications.[37] Low infection rates have 
been observed in patients with risk factors for infective 
complications who had long-term antibiotic prophylaxis 
following prostate biopsy compared to their counterparts who 
had short-term antibiotic prophylaxis.[13] Aus et al.[13] reported 
an infection rate of 4.9% in patients who received 400 mg 
norfloxacin twice daily for one week and 11% in patients 
who received 400 mg norfloxacin twice daily for one day. 
In their study, they included patients with diabetes, UTI, and 
indwelling urethral catheters. The most pronounced effect of 
the one-week regimen was noted in patients with risk factors 
for infection.
In this study, diabetics were noted to have a statistically 
significant higher risk of infective complications following 
three-day antibiotic prophylaxis. On the other hand, their 
counterparts who had seven-day antibiotic prophylaxis did not 
have a higher occurrence of infective complications [Tables 3 
and 4]. Patients with hypertension, presence of a urethral 
catheter, antibiotics use within 14 days before biopsy, 
hospitalization within 14 days before TNBP, or prolonged 
steroid use did not have a high risk of infective complications 
following prostate biopsy. This suggests that patients who are 
diabetics may fare better, in terms of infective complications, 
when placed on a seven-day antibiotics regimen.
E coli was the most common organism isolated in this study, 
with a good sensitivity to the cephalosporins. This observation 
is in consonance with findings from similar works.[6,9,11] This 
suggests that cephalosporins can be used in the treatment of 
infective complications developing after prostate biopsy.
conclusIon
TNBP has a low incidence of major complications. A three-day 
prophylactic oral ciprofloxacin and metronidazole regimen is 
effective for prophylaxis in TNBP. A seven‑day regimen is, 
however, recommended in patients who are diabetics before TNBP. 
Quinolone-resistant E. coli was the most common microorganism 
in infections occurring after TNBP under quinolone–metronidazole 
prophylaxis. The most effective antibiotic in infections caused by 
quinolone-resistant organisms was cephalosporin.
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